GUARDCAP ASSET MANAGEMENT Ltd Purchases New Stake in Stryker Co. (SYK)
GUARDCAP ASSET MANAGEMENT Ltd purchased a new stake in Stryker Co. (NYSE:SYK) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 90,704 shares of the medical technology company’s stock, valued at approximately $14,045,000. Stryker accounts for approximately 5.9% of GUARDCAP ASSET MANAGEMENT Ltd’s holdings, making the stock its 9th largest holding.
A number of other hedge funds have also modified their holdings of the business. Sei Investments Co. lifted its position in shares of Stryker by 26.8% during the 3rd quarter. Sei Investments Co. now owns 41,104 shares of the medical technology company’s stock worth $5,838,000 after purchasing an additional 8,696 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Stryker by 1.1% during the 3rd quarter. New York State Common Retirement Fund now owns 1,106,000 shares of the medical technology company’s stock worth $157,074,000 after purchasing an additional 11,800 shares during the last quarter. Advisors Asset Management Inc. lifted its position in shares of Stryker by 11.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 27,989 shares of the medical technology company’s stock worth $3,975,000 after purchasing an additional 2,948 shares during the last quarter. Buckingham Capital Management Inc. lifted its position in shares of Stryker by 9.4% during the 3rd quarter. Buckingham Capital Management Inc. now owns 10,521 shares of the medical technology company’s stock worth $1,494,000 after purchasing an additional 905 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Stryker by 3.5% during the 3rd quarter. Macquarie Group Ltd. now owns 110,720 shares of the medical technology company’s stock worth $15,724,000 after purchasing an additional 3,700 shares during the last quarter. 75.68% of the stock is owned by institutional investors.
In other news, VP Yin C. Becker sold 23,221 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the transaction, the vice president now directly owns 10,499 shares in the company, valued at $1,742,414.04. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,730 shares of company stock worth $16,360,442. Company insiders own 7.40% of the company’s stock.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The company had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the business posted $1.78 earnings per share. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts anticipate that Stryker Co. will post 7.12 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.14%. Stryker’s dividend payout ratio (DPR) is 70.15%.
Several equities research analysts have recently issued reports on SYK shares. JPMorgan Chase & Co. raised shares of Stryker from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Zacks Investment Research lowered shares of Stryker from a “hold” rating to a “sell” rating in a research note on Saturday, January 20th. BMO Capital Markets upgraded shares of Stryker to a “market perform” rating and set a $163.00 price target on the stock in a research note on Tuesday, December 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $163.00 price target on shares of Stryker in a research note on Friday, January 5th. Finally, Morgan Stanley lifted their price target on shares of Stryker from $179.00 to $186.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $164.76.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/03/22/guardcap-asset-management-ltd-purchases-new-stake-in-stryker-co-syk.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.